Press Releases

Sequent Medical Appoints Mike Kleine to its Board of Directors

ALISO VIEJO, CALIFORNIA – July 07, 2015 – Sequent Medical, a privately held medical device company focused on developing innovative devices for the treatment of neurovascular disease, announced today that R. Michael Kleine has joined its Board of Directors.

Mr. Kleine has over 25 years of medical device and healthcare industries experience. He has successfully managed several global biomedical companies where he has commercialized numerous leading-edge products. His experience encompasses a wide range of global markets, product life-cycles, new product launches, acquisitions and integrations.

“We welcome the additional experience and leadership that Mike brings to Sequent, and we look forward to the new insights he will provide for our continued rapid growth and global product commercialization,” said Tom Wilder, CEO of Sequent Medical. “Mike is a seasoned healthcare executive with direct neurovascular business experience. His capabilities will be a valuable asset as we continue to grow our core WEB™ franchise while also expanding our neurovascular product portfolio.”

Mr. Kleine is currently President and Chief Executive Officer of Miramar Labs, Inc., a privately owned medical device company dedicated to bringing next generation energy modalities to the field of dermatology. Prior to joining Miramar, Mr. Kleine served as President & CEO of both EndoGastric Solutions and Biosensors International Group, a Singapore-based maker of interventional cardiology and critical care products. During his tenure at publicly traded Biosensors, he grew the market cap from $187 million to $662 million.

From 2002 to 2006, Mr. Kleine served as President and Chief Executive Officer at Microvention Inc., a leading developer, manufacturer and marketer of minimally invasive products for treatment of neurovascular and peripheral diseases. During his tenure he successfully managed the rapid growth of the company until its acquisition by Terumo Corporation in 2006.

Prior to Microvention, Mr. Kleine led a series of other medical technology companies including Pharos LLC, Thermo Cardiosystems (acquired by Thoratec), Sorin Biomedical (merged with Cobe, Inc.), and Bird Medical Technologies. Mr. Kleine’s early career includes over 13 years at Baxter in a variety of commercial roles. Mr. Kleine holds a Masters Degree from Webster University and a Bachelor of Arts in Biological Science from Missouri Valley College.

"Sequent’s business is experiencing significant momentum, and I am pleased to be joining the Board at such a critical juncture in the Company's history," said Mr. Kleine. "I look forward to leveraging my commercial and operational expertise as the Company enters a dynamic phase of growth and expansion."

About Sequent Medical, Inc.
Founded in 2007, Sequent Medical, Inc. is a privately held venture backed medical device company that is dedicated to the development of innovative catheter-based neurovascular technologies. The WEB Aneurysm Embolization System and VIA® Microcatheter have both received the CE mark. The VIA has been cleared for commercial use in the United States. In the United States, the WEB is an investigational device limited by United States law to investigational use. Sequent is headquartered in Aliso Viejo, California, and has European operations based in Bonn, Germany.

About The WEB Aneurysm Embolization System
Building upon the foundation of endovascular embolic coils, the WEB is an intrasaccular flow disrupter designed to bridge the neck of a ruptured or unruptured intracranial aneurysm and to promote rapid, peri-procedural stasis. The WEB is based upon Sequent Medical’s proprietary MicroBraidTM technology, a dense mesh constructed from a large number of extremely fine Nitinol wires. Unlike conventional medical braids, MicroBraid features a mix of wire diameters to achieve a tailored balance of compliance, porosity and profile across device sizes.

The WEB enables physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials. To date, the WEB has been used to treat over 1,700 ruptured and unruptured aneurysms worldwide.